Pesquisas alternativas:
compra como » compras como (Expandir a Pesquisa), comparado como (Expandir a Pesquisa), compleja como (Expandir a Pesquisa)
pcsk9 can » pcsk9 gain (Expandir a Pesquisa), pcsk9 mab (Expandir a Pesquisa)
a compra » la compra (Expandir a Pesquisa), da compra (Expandir a Pesquisa), na compra (Expandir a Pesquisa)
como neo » como nexo (Expandir a Pesquisa), como nao (Expandir a Pesquisa), como new (Expandir a Pesquisa)
pcsk9 a » pcsk9 _ (Expandir a Pesquisa)
A mostrar 1 - 20 resultados de 101 para a pesquisa '(( j a ((pcsk9 can) OR (pcsk9 a)) new ) OR ( _ a compra como neo ))*', tempo de pesquisa: 0.59seg Refinar resultados
Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
PCSK9 inhibitors: A new era of lipid lowering therapy

Lipid Lowering Therapy and Circulating PCSK9 Concentration
PCSK9 signaling pathways and their potential importance in clinical practice

Erratum to: PCSK9 inhibitors in the prevention of cardiovascular disease
Using human ‘experiments of nature’ to predict drug safety issues: an example with PCSK9 inhibitors

AAV8-mediated overexpression of mPCSK9 in liver differs between male and female mice
The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Active Site and Cleavage Sequence Differentially Regulate Protein Secretion from Proteolysis

Characteristics of patients with diabetes and a history of myocardial infarction initiating PCSK9 and SGLT2 inhibitors
Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis

Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs
The PCSK9 decade: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases

A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
PCSK9 - A New and Potent Approach to Lowering Cholesterol

Evidence for Positive Selection in the C-terminal Domain of the Cholesterol Metabolism Gene PCSK9 Based on Phylogenetic Analysis in 14 Primate Species
Inhibition of PCSK9 Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway

A new method for measurement of total plasma PCSK9: clinical applications
Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Ferramentas de pesquisa: Obter Feed RSS — Enviar pesquisa por email — Guardar a pesquisa